🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

There is one month left for you to submit an abstract or apply for a Travel Grant to attend Liquid Biopsies 2024! Always a popular EACR conference, don't miss hearing from recognised experts in many aspects of liquid biopsy research. Apply by 16 Sept: eacr.org/conference/liq…

Metastatic luminal breast cancer treatment has changed and it will continue to change. This is an important review to understand these changes. NatureRevClinOncol. doi.org/10.1038/s41571….

PALLAS trial, important information about prognostic in stage IIA vs IIB/III RH+ early breast cancer. 👉 pubmed.ncbi.nlm.nih.gov/39849600/

Great app Timothée Olivier, MD. Vinay Prasad MD MPH

This article meticulously explores the importance of a molecular tumor board team, and it helps to structure. ESMO - Eur. Oncology 👉 sciencedirect.com/science/articl…

An important question in daily practice for these patients with low expression of HR. It is essential to put it in context with works as ebctcg with no beneficial data with tamoxifen addition in ER < 10%. ER 1-5% no OS gain (HR p .24). 👉 ascopubs.org/doi/10.1200/JC… Journal of Clinical Oncology

Wonderful educational session. Beyond ER backbones. Treatment of luminal cancer keeps evolving. #esmobreast2025 Sara Tolaney

APHINITY OS 11y FU: 👉ITT: 91.6 vs 89.8% HR 0.83 p0.0441 👉N+: 89.6 vs 86.9% HR 0.79 #ESMOBreast25 ESMO - Eur. Oncology

PostMonarch data: Benefit across most subgroups. #esmobreast2025

Discover top social influencers from #esmobreast25 Yakup Ergün Paolo Tarantino Guilherme Nader Marta Sara Tolaney Matteo Lambertini, MD PhD Aumilto Silva, MD. Evandro de Azambuja, MD, PhD Janice Cowden Nancy Lin, MD

The molecular profiling has become fundamental to planning the treatment for breast cancer, and much more is going to come. Interesting review. The Breast Online JAVIER CORTES 👉 thebreastonline.com/article/S0960-…